Your session is about to expire
← Back to Search
Elotuzumab + Lenalidomide for Multiple Myeloma
Study Summary
This trial is studying how well elotuzumab works with lenalidomide as maintenance therapy after transplant in patients with newly diagnosed multiple myeloma who underwent transplant using their own stem cells.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 170 Patients • NCT02726581Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer has spread to my brain or spinal cord.I have active hepatitis B or C.I still have mild or no side effects from my last chemotherapy.I can take care of myself and am up and about more than half of my waking hours.I cannot take pills by mouth or have a GI condition that affects medication absorption.I changed my primary cancer treatment due to poor response or side effects, but haven't tried more than 2 treatments before stem cell transplant.I haven't needed IV antibiotics in the last 7 days.I had a stem cell transplant within 18 months after starting treatment for newly diagnosed myeloma.I can start maintenance therapy between 60 to 210 days after my transplant, meeting specific health criteria.I meet the study's requirements for contraception or am not of childbearing potential.I have not had radiotherapy in the last 14 days.I have not had major surgery in the last 2 weeks.I am currently pregnant or breastfeeding.
- Group 1: Treatment (elotuzumab, lenalidomide)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is recruitment for this experiment currently taking place?
"The information stored on clinicaltrials.gov suggests that this particular medical trial is not actively recruiting patients at present, despite having been first posted in April 2015 and last updated in September 2022. However, 1103 other studies are currently enrolling participants."
To what extent does Elotuzumab present a risk to those using it?
"Our team assigned Elotuzumab a score of 2, as this is still in the Phase 2 stage with limited data on its efficacy but some evidence supporting safety."
How many individuals are being included in this clinical investigation?
"At this current juncture, the trial is not actively enrolling patients. It was initially posted on April 14th 2015 and last updated on September 22nd 2022. If you're searching for other research opportunities, there are 824 clinical trials related to hematopoietic cell transplantation recipient enrolment and 279 studies with Elotuzumab recruiting individuals right now."
To what afflictions is elotuzumab commonly prescribed?
"Elotuzumab is usually indicated for multiple myeloma treatment, but can also be employed to treat relapsed and/or refractory lymphoma, chronic lymphocytic leukemia, or in cases where two prior systemic chemotherapy regimens have been unsuccessful."
Share this study with friends
Copy Link
Messenger